Stressgen - wie gehts weiter? - 500 Beiträge pro Seite

[KBlaubaer08]

Hi Leute,
was ist Eure Meinung wie es nächste Woche bei der stressigen Aktie weitergeht? ...hat einer neue Info`s wie es mit den Zauber-Mittelchen in Phase II und III ausssieht?
Gruß K`Blaubär

[KBlaubaer08]

Hi Leute,
bin gestern aus dem Urlaub , hatte heute voll Stress... schreibt doch mal was! Ich muß erst mal auf die Suche gehen, sieht ja im Moment nicht sehr nördlich aus der Kurs...
Tschö

[KBlaubaer08]

mit Übersetzungsprogramm aus dem englischen...

QUELLE: StressGen Biotechnologies Corp. StressGen berichtet über Resultate des zweiten Viertels für 2000 VICTORIA BC Aug. 15 / CNW-PRN / - StressGen Biotechnologies Corp. gaben heute seine finanziellen Resultate für das beendete Viertel Juni 30, 2000 frei. Die Firma berichtete über Einkommen von ungefähr $2,66 Million für die ersten sechs Monate von 2000, verglichen bis $1,96 Million berichtet 1999. Diese Zunahme ist 22 % Steigerung der biochemischen Produktverkäufe von $1,55 Million für die ersten sechs Monate von 1999 bis $1,88 Million für die ersten sechs Monate von 2000 zuzuschreibend. Wachstum in den Einkommen ist auch einer Zunahme des Interesses und anderen Einkommens von $0,41 Million für die ersten sechs Monate von 1999 bis $0,77 Million während der gleichen Periode von 2000 zuzuschreibend. Bargeld und kurzfristige Investitionen entsprachen $36,12 Million an Juni 30, 2000. Die Firma meldete Reinverluste von 5.85 Million oder $0,17 Cents pro den allgemeinen Anteil, der mit einem Reinverlust von 4.26 Million oder $0,14 Cents pro allgemeinen Anteil während der gleichen Periode 1999 verglichen wurde. Für die sechs Monate beendet Juni 30, meldeten 2000, die Firma Reinverluste von 10.16 Million oder $0,29 Cents pro den allgemeinen Anteil, der mit einem Reinverlust von 7.64 Million oder $0,26 Cents pro allgemeinen Anteil an der gleichen Periode 1999 verglichen wurde. Die Zunahmen der Verluste im Verhältnis zu 1999 reflektieren die Zuführungen in den klinischen Programmen, in der Forschung und in den allgemeinen und administrativen Kosten. vor ``Since archivierten wir unseren IND für HspE7 18 Monaten, sind wir schnell durch Phase I und II Versuche weitergekommen und wurden vor kurzem mit den positiven Resultaten belohnt, die Beweis der Grundregel für unsere Schmelzverfahren Proteintechnologie bestätigen und offenbar anzeigen, daß HspE7 einen therapeutischen Nutzen bei Patienten hat, ` ` sagten Daniel Korpolinski, Präsident und CEO von StressGen. Er fügte hinzu, werden ``We jetzt in Position gebracht, um Versuche der Phase III einzutragen und unsere erhöhten Aufwendungen in der klinischen Entwicklung werden angefordert, um sicherzugehen, daß die bedeutende und schnelle Zuführung unserer klinischen Programme fortfährt. Wir haben die zweite Jahreshälfte auf einer sehr starken Anmerkung begonnen und sind überzeugt, daß diese Tendenz fortfährt für den Rest von 2000. ` `, StressGen Biotechnologies Corporation wird auf die Entwicklung und die Kommerzialisierung des proteinbasierten immunotherapeutics des Romanhitze-Schlages für die Behandlung der virally verursachten Infektion und der Krebse gerichtet. Das Produkt HspE7 Leitung der Firma zielt HPV (menschliches papillomavirus) das für eine Vielzahl der prekanzerösen und cancerous Bedingungen verantwortlich ist. StressGen hat eine aktive Studie HspE7 der Phase II in den Frauen mit hochwertigem zervikalem Dysplasia und Plänen zum Initialisieren eines Versuches HspE7 der Phase II für zervikalen Krebs sowie einen AIN-Versuch der Phase III. Zusätzlich wird StressGen das klinische Programm HspE7 erweitern, um genitale Warzen mit einzuschließen. Die Firma entwickelt eine ausgedehnte Strecke der proteinbasierten therapeutischen Produkte des Druckes für andere Krankheiten einschließlich der Hepatitis und HIV und hat auch Studien initialisiert, um die Hitzeschlagproteine im Asthma und in der Allergie auszuwerten. Durch seine biochemische Abteilung ist StressGen ein international anerkannter Lieferant der Forschung Produkte für die Studie des zellularen Druckes, des apoptosis, des oxydierenden Druckes und der Neurobiologie. Diese Produkte werden von den Wissenschaftlern weltweit benutzt. Die Stoffe, die in diesen Nachrichten enthalten werden, geben einschließlich frei, aber begrenzt nicht auf klinische Versuche, Vorwärts-forward-looking regelnde Stoffe, Glaube und Erwartungen Anweisungen. StressGen geht keine Verbindlichkeit ein, die Resultate jeder möglicher Änderung zu diesen Vorwärts-forward-looking Anweisungen öffentlich freizugeben, um Fälle oder Umstände nach dem Datum hiervon zu reflektieren oder das Auftreten der unvorhergesehenen Fälle zu reflektieren.

aber gut... interessiert ja niemand hier, bin wohl der einzige der stressgen hält (ja leider schon seit März)
Gruß KB

[ErnieEarn]

Hi KB,

bist nicht der Einzige.....habe leider keine Zeit research für Stressgen zu machen, lese aber immer wenn was kommt. Die Zahlen sind nicht berauschend, allerdings weiß ich nicht was o die Analysten erwartet haben. Ich gebe dem Baby noch viel Zeit sich zu entwickeln!
Übrigens wie heißt Deine ausgezeichnete Überstzungssoftware??? Bei meiner kommt nur zusammenhangloser Schrott raus?!
Gruß und betse Kurse
EE

[ErnieEarn]

hi KB,

bist nicht der Einzige....habe nur leider keine Zeit für alle meine Aktien ausführlichen research zu betreiben! Die Zahlen sind nicht berauschend, was für ein Startup nicht schlimm ist, vorausgestzt die Analysten haben nicht mehr erwartet, dann gibts Ärger...
Deine Übersetzungssoftware ist super!!! Sag mal wie die heißt, bei meiner kommt nur übler Schrott raus...
Ich gebe dem Baby übrigens noch viel Zeit sich zu entwickeln, solltest Du auch!
Gruß und beste Kurse
EE

[Dr.Hook]

Hi KBlaubär08,
ich hab zwar keine Neuigkeiten, wollte Dich aber als Leidensgenossen grüßen.
(Das geht ja nicht, daß Du der einzige bist, der auf Deinen Thread antwortet!)
Halte meine Stressgen auch seit Anfang März zum Mischkurs 7,35)
Der heutige Kurs macht ja nun auch nicht grade Freude.
Aber: ich geb die Hoffnung nicht auf!!
PS: Nimm´s mir nicht übel, aber das Übersetzungsprogramm taugt nicht viel

Gruß
Dr.Hook

[KBlaubaer08]

@Ernie
Übersetzungsprogramm ist eben nur ein Notnagel, ich lese es aber gern so, als mir einen in englisch abzuquälen. Einzelne Fakten kann man ja im Original lesen... zumindest meine Meinug.
http://www.babelfish.altavista.com/translate.dyn

Jo Leute, wo geht es nun hin mit Stressgen, ich hoffe nach Norden!
Gruß KB

[ErnieEarn]

hi KB,

war nicht ironisch gemeint unter den bisher gesehenen Texten ist dieser wirklich!!! einer der best übersetzten...
Gruß und beste Kurse
EE

[KBlaubaer08]

hmm, nun laßt uns mal was tun, damit die Aktie wieder nördlich wandert
Gruß KB

[Mammon77]

KZ: DAUSEND!!! Ich hoffe aber auf einen mittleren bis höheren 2-Stelligen Kurs bis zum Jahresende??

[Andrax]

es tut sich mal wieder was....

StressGen reports data on recombinant fusion protein HspE7 mechanism of action




Clin. Exp. Immunol. Paper Also Highlights Potential Novel

Therapeutic Approach for Immunocompromised Patient Population


VICTORIA, BC, Aug. 21 /CNW/ - StressGen Biotechnologies Corp. (TSE: SSB) announced today the publication of data demonstrating that its lead product, HspE7, a recombinant fusion protein, invokes a potent cytotoxic T cell response. This type of immune response is important for clearance of viral infections and cancers. In addition, HspE7 activity is shown to be CD4+ independent. This supports the potential application of StressGen`s novel therapeutic approach in the treatment of immunocompromised patients, whose CD4+ T cells are depleted or significantly impaired. This report appears in the journal of Clinical and Experimental Immunology (121:216-225). These preclinical studies clearly indicate that the recombinant fusion protein is required for tumor regression and long-term survival. Components of the fusion protein, alone or in a mixture, are not effective.

HspE7, a recombinant fusion protein, is composed of heat shock protein 65 (Hsp65) from Mycobacterium-bovis BCG and the protein E7. As a member of the family of stress proteins, Hsp65 is known to elicit a powerful immune response. The E7 protein is an antigen derived from the Human Papillomavirus (HPV) and is involved in the malignant transformation of anal and cervical epithelial cells. E7 is a tumor-specific antigen and thus represents a precise target for the immune system attack on HPV infected cells, leaving normal tissues unharmed.

"This publication reinforces StressGen`s position at the forefront of heat shock protein based immunotherapeutics and further supports the utility of the fusion protein in expanding our pipeline," said Daniel Korpolinski, President and CEO of StressGen. "Our plans include programs for other infectious diseases such as Hepatitis and also HIV."

These studies extend previous observations including those previously reported by some of StressGen`s collaborators at MIT on the mechanism of action of Hsp fusion proteins and are consistent with the clinical application of HspE7 as an immunotherapy for HPV-related diseases such as cervical and anal dysplasia and cancer. HspE7 is based on Stressgen`s proprietary fusion protein platform technology.


StressGen Biotechnologies Corporation is focused on the development and commercialization of novel heat shock protein-based immunotherapeutics for the treatment of virally induced infections and cancers. The Company`s lead product HspE7 targets HPV (human papillomavirus) which is responsible for a variety of precancerous and cancerous conditions. StressGen has an active phase II HspE7 study in women with high-grade cervical dysplasia and plans to initiate a phase II HspE7 trial for cervical cancer as well as a phase III AIN trial. In addition, StressGen will be expanding the HspE7 clinical program to include genital warts. The Company is developing a broad range of stress protein-based therapeutic products for other diseases including hepatitis and HIV and has also initiated studies to evaluate the heat shock proteins in asthma and allergy. Through its Biochemical Division, StressGen is an internationally recognized supplier of research products for the study of cellular stress, apoptosis, oxidative stress and neurobiology. These products are used by scientists worldwide.


The matters contained in this news release including, but not limited to clinical trials, regulatory matters, beliefs, and expectations are forward-looking statements. StressGen undertakes no obligation to publicly release the results of any revision to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

%SEDAR: 00002379E

[ErnieEarn]

News out....

Monday August 21, 8:00 am Eastern Time
Press Release
SOURCE: StressGen Biotechnologies Corp.
StressGen reports data on recombinant fusion protein HspE7 mechanism of action
Clin. Exp. Immunol. Paper Also Highlights Potential Novel Therapeutic Approach for Immunocompromised Patient Population
VICTORIA, BC, Aug. 21 /CNW-PRN/ - StressGen Biotechnologies Corp. (TSE: SSB - news) announced today the publication of data demonstrating that its lead product, HspE7, a recombinant fusion protein, invokes a potent cytotoxic T cell response. This type of immune response is important for clearance of viral infections and cancers. In addition, HspE7 activity is shown to be CD4+ independent. This supports the potential application of StressGen`s novel therapeutic approach in the treatment of immunocompromised patients, whose CD4+ T cells are depleted or significantly impaired. This report appears in the journal of Clinical and Experimental Immunology (121:216-225). These preclinical studies clearly indicate that the recombinant fusion protein is required for tumor regression and long-term survival. Components of the fusion protein, alone or in a mixture, are not effective.

HspE7, a recombinant fusion protein, is composed of heat shock protein 65 (Hsp65) from Mycobacterium-bovis BCG and the protein E7. As a member of the family of stress proteins, Hsp65 is known to elicit a powerful immune response. The E7 protein is an antigen derived from the Human Papillomavirus (HPV) and is involved in the malignant transformation of anal and cervical epithelial cells. E7 is a tumor-specific antigen and thus represents a precise target for the immune system attack on HPV infected cells, leaving normal tissues unharmed.

``This publication reinforces StressGen`s position at the forefront of heat shock protein based immunotherapeutics and further supports the utility of the fusion protein in expanding our pipeline,`` said Daniel Korpolinski, President and CEO of StressGen. ``Our plans include programs for other infectious diseases such as Hepatitis and also HIV.``

These studies extend previous observations including those previously reported by some of StressGen`s collaborators at MIT on the mechanism of action of Hsp fusion proteins and are consistent with the clinical application of HspE7 as an immunotherapy for HPV-related diseases such as cervical and anal dysplasia and cancer. HspE7 is based on Stressgen`s proprietary fusion protein platform technology.

StressGen Biotechnologies Corporation is focused on the development and commercialization of novel heat shock protein-based immunotherapeutics for the treatment of virally induced infections and cancers. The Company`s lead product HspE7 targets HPV (human papillomavirus) which is responsible for a variety of precancerous and cancerous conditions. StressGen has an active phase II HspE7 study in women with high-grade cervical dysplasia and plans to initiate a phase II HspE7 trial for cervical cancer as well as a phase III AIN trial. In addition, StressGen will be expanding the HspE7 clinical program to include genital warts. The Company is developing a broad range of stress protein-based therapeutic products for other diseases including hepatitis and HIV and has also initiated studies to evaluate the heat shock proteins in asthma and allergy. Through its Biochemical Division, StressGen is an internationally recognized supplier of research products for the study of cellular stress, apoptosis, oxidative stress and neurobiology. These products are used by scientists worldwide.

The matters contained in this news release including, but not limited to clinical trials, regulatory matters, beliefs, and expectations are forward-looking statements. StressGen undertakes no obligation to publicly release the results of any revision to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

SOURCE: StressGen Biotechnologies Corp.


Email this story - View most popular


Gruß und beste Kurse
EE

[KBlaubaer08]

ok, danke für die Infos
ich mache mal wieder ein häßliches deutsch draus, geht vielleicht anderen auch so wie mir....

StressGen berichtet über Daten bezüglich der recombinant Einheit des Schmelzverfahren Proteins HspE7 der Tätigkeit Clin. Exp. Immunol. Papier markiert auch therapeutische Annäherung des möglichen Romans für geduldige Bevölkerung VICTORIA Immunocompromised BC Aug. 21 / CNW-PRN / - StressGen Biotechnologies Corp. (TSE: SSB - Nachrichten) heute verkündet der Publikation der Daten, die zeigen, daß sein Leitung Produkt, HspE7, ein recombinant Schmelzverfahren Protein, eine starke cytotoxische t-Zelle Antwort hervorruft. Diese Art der immunen Antwort ist für Abstand von Vireninfektion und von Krebsen wichtig. Zusätzlich wird Aktivität HspE7 gezeigt, um unabhängiges CD4+ zu sein. Dieses unterstützt die mögliche Anwendung des StressGen`s-Romans, den therapeutische Annäherung in der Behandlung von Patienten immunocompromised, deren Zellen CD4+ T verbraucht werden oder erheblich gehindert. Dieser Report erscheint im Journal der klinischen und experimentellen Immunitätsforschung (121:216-225). Diese preclinical Studien zeigen offenbar an, daß das recombinant Schmelzverfahren Protein für Tumorrückbildung und langfristiges Überleben angefordert wird. Bestandteile des Schmelzverfahren Proteins, alleine oder in einer Mischung, sind nicht wirkungsvoll. HspE7, ein recombinant Schmelzverfahren Protein, besteht aus Hitzeschlagprotein 65 (Hsp65) vom Mykobakterium-bovis BCG und dem Protein E7. Als Bauteil der Familie der Druckproteine, bekannt Hsp65, um eine leistungsfähige immune Antwort herauszubekommen. Das Protein E7 ist ein Antigen, das vom menschlichen Papillomavirus (HPV) berechnet wird und wird in die bösartige Transformation der analen und zervikalen Epithelzellen miteinbezogen. E7 ist ein Tumor-spezifisches Antigen und stellt folglich ein exaktes Ziel für den Angriff des immunen Systems auf HPV angesteckten Zellen dar und verläßt normale Gewebe unharmed. ``This-Publikation verstärkt StressGen`s-Position an der vordersten Reihe des gegründeten immunotherapeutics des Hitzeschlages Protein und unterstützt weiter das Hilfsprogramm des Schmelzverfahren Proteins, wenn sie unsere Rohrleitung, ` ` sagte Daniel Korpolinski, Präsident und CEO von StressGen erweitert. ``Our-Pläne umfassen Programme für andere ansteckende Krankheiten wie Hepatitis und auch HIV. ` `,
Diese Studien dehnen vorhergehende Beobachtungen einschließlich deren aus, die vorher von einigen von StressGen`s-Mitarbeitern an MIT auf der Einheit der Tätigkeit der Proteine Schmelzverfahren Hsp berichtet werden und sind mit der klinischen Anwendung von HspE7 als Immunotherapy für HPV-relatedkrankheiten wie zervikalen und analen Dysplasia und Krebs gleichbleibend. HspE7 basiert auf Protein-Plattformtechnologie Schmelzverfahren Stressgen eigener. StressGen Biotechnologies Corporation wird auf die Entwicklung und die Kommerzialisierung des proteinbasierten immunotherapeutics des Romanhitze-Schlages für die Behandlung der virally verursachten Infektion und der Krebse gerichtet. Das Produkt HspE7 Leitung der Firma zielt HPV (menschliches papillomavirus) das für eine Vielzahl der prekanzerösen und cancerous Bedingungen verantwortlich ist. StressGen hat eine aktive Studie HspE7 der Phase II in den Frauen mit hochwertigem zervikalem Dysplasia und Plänen zum Initialisieren eines Versuches HspE7 der Phase II für zervikalen Krebs sowie einen AIN-Versuch der Phase III. Zusätzlich wird StressGen das klinische Programm HspE7 erweitern, um genitale Warzen mit einzuschließen. Die Firma entwickelt eine ausgedehnte Strecke der proteinbasierten therapeutischen Produkte des Druckes für andere Krankheiten einschließlich der Hepatitis und HIV und hat auch Studien initialisiert, um die Hitzeschlagproteine im Asthma und in der Allergie auszuwerten. Durch seine biochemische Abteilung ist StressGen ein international anerkannter Lieferant der Forschung Produkte für die Studie des zellularen Druckes, des apoptosis, des oxydierenden Druckes und der Neurobiologie. Diese Produkte werden von den Wissenschaftlern weltweit benutzt. Die Stoffe, die in diesen Nachrichten enthalten werden, geben einschließlich frei, aber begrenzt nicht auf klinische Versuche, Vorwärts-forward-looking regelnde Stoffe, Glaube und Erwartungen Anweisungen. StressGen geht keine Verbindlichkeit ein, die Resultate jeder möglicher Änderung zu diesen Vorwärts-forward-looking Anweisungen öffentlich freizugeben, um Fälle oder Umstände nach dem Datum hiervon zu reflektieren oder das Auftreten der unvorhergesehenen Fälle zu reflektieren. QUELLE: StressGen Biotechnologies Corp.

Na denn, weiter nach Norden!
Gruß KB

[Dr.Hook]

Hallo!
Hmh... Stressgen streßt mal wieder. Sieht nicht nach nördlicher Bewegung aus...
Für das Verstehen der Übersetzung braucht man aber viel Phantasie...!
Was um Himmels willen ist denn der "Roman-Hitzeschlag"??
Grüße
Dr.Hook

[KBlaubaer08]

Hi Leute,
ich glaube es tut sich was bei unserem Liebling. Ich denke wir schaffen heute noch die 8$ in Toronto, sieht gut aus. Na dann auf hoffentlich gute nächste Tage.
Gruß KB

[Andrax]

aktuell 9,20 CDN $ + 8,88%

[Andrax]

Grund für die neuerlichen Kursgewinne ist vielleicht ein neues Patent das Stressgen in den USA angemeldet hat. Leider bin ich zu dämlich hier einen Link reinzustellen, aber hier ist die webadresse:
http://164.195.100.11 ( ist ne datenbank für patentanmeldungen ) dann unter " boolean search " stressgen" eingeben. Die Patentanmeldung ist von gestern, 29.08.00.

[Andrax]

StressGen initiates HspE7 Phase II Trial in cervical cancer
08:00 EDT Wednesday, September 06, 2000


Heat Shock Fusion Protein - A Novel Therapeutic for HPV-Related Diseases

VICTORIA, BC, Sept. 6 /CNW/ - StressGen Biotechnologies Corp. (TSE: SSB) announced today that it has initiated patient treatment in its Phase II clinical trial to investigate HspE7, a novel immunotherapeutic, as a treatment for advanced cancer of the uterine cervix caused by the human papillomavirus (HPV). This disease is associated with extreme morbidity and is always fatal when surgery and radiotherapy fail.

HspE7, a recombinant fusion product, is composed of heat shock protein 65 (Hsp65) from Mycobacterium-bovis BCG and the protein E7. As a member of the family of stress proteins, Hsp65 is known to elicit a powerful immune response. The E7 protein is derived from the human papillomavirus (HPV) and is involved in the malignant transformation of anal and cervical epithelial cells. E7 is a tumor-specific antigen and thus represents a precise target for the immune system attack on abnormal cells. HspE7 is based on Stressgen`s proprietary fusion protein platform technology. StressGen also has an active phase II HspE7 study in women with HPV-related cervical dysplasia (CIN), and plans to initiate a phase III trial in HPV-related anal dysplasia (AIN).

HPV causes 90-99+% of cervical cancers. Cervical infection with HPV commonly results in the development of abnormal or dysplastic cells are usually detected in women through regular Pap smear screening. Left undiagnosed, dysplastic cells can become cancerous. It is estimated that 1.5 million women in the United States will be diagnosed with some form of HPV- related cervical dysplasia. HPV is also responsible for genital warts and is the causative agent of laryngeal warts as well as some head and neck cancers.

Cervical cancer is a global public health problem, particularly in countries where routine PAP smears are not practiced. Globally there are approximately 500,000 new cases of cervical cancer identified each year resulting in nearly 300,000 deaths. Each year in the U.S. 15,000 women are diagnosed with cervical cancer and 5,000 die from cervical cancer.

"Clearly a need exists to develop better treatments," said Daniel Korpolinski, President and CEO of StressGen Biotechnologies. "Promising results from our HspE7 clinical program and earlier phase studies suggest that our approach could offer a new therapy for patients with advanced cervical cancer".

In the Phase II cervical cancer trial, StressGen will employ proprietary heat shock fusion protein immunotherapy, HspE7, which the Company developed to treat HPV-related diseases such as cervical cancer and anal dysplasias. The study requires each patient to receive multiple injections of HspE7. Clinical efficacy will be measured by conventional oncologic criteria.


StressGen Biotechnologies Corporation is a biopharmaceutical company focused on the development and commercialization of innovative stress protein-based immunotherapeutics. The Company`s lead product, HspE7, is in Phase II trials for CIN and AIN. StressGen plans to initiate an HspE7 Phase III AIN trial and a clinical trial in genital warts. The Company is developing a broad range of stress protein-based therapeutic products for the treatment of virally-induced infections and cancers, Hep B and HIV. StressGen has also initiated studies to evaluate the technology in asthma and allergy. Through its Biochemical Division, StressGen is also an internationally recognized supplier of research products for the study of cellular stress, apoptosis, oxidative stress and neurobiology. These products are used by scientists worldwide.


The matters contained in this news release including, but not limited to clinical trials, regulatory matters, beliefs, and expectations are forward-looking statements. StressGen undertakes no obligation to publicly release the results of any revision to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

%SEDAR: 00002379E

[Mr.Performance]

Was meint ihr, wie geht´s weiter?

Gruß
Mr.P

[STOCKMASTERNO1]

hab kein vertrauen in das Teil

[study]

@STOCKM....
wo bleibt deine Begründung?
Ansonsten verschone uns bitte mit deinen Glaubenskrisen...BITTE!

[tork]

Hallo,

heute mal wieder richtig abwärts, wie wir das ja leider schon gewohnt sind. Kein halten mehr bis 3,50 € ? Weiß jemand etwas ? Vielleicht
BiotechGuru, du Komiker !!!

[toller]

stressgen gibt wohl neue aktien aus...

Wednesday September 20, 4:05 pm Eastern Time
Press Release
SOURCE: StressGen Biotechnologies Corp.
StressGen announces public offering
VICTORIA, BC, Sept. 20 /PRNewswire/ - StressGen Biotechnologies Corp. (TSE: SSB - news) announced today that it has filed a short form preliminary prospectus in Canada and a registration statement in the United States under the Canada/U.S. multi-jurisdictional disclosure system in connection with a public offering of Common Shares.

The underwriting syndicate for the offering will be led by BMO Nesbitt Burns Inc., and includes CIBC World Markets Inc. and Goepel McDermid Inc. The Company"s marketing period is expected to commence on or about September 20, 2000. The offering is expected to close by mid-October 2000.

The net proceeds of this offering will be used to fund the Company"s development program for its lead product candidate HspE7, to fund the research and development of new product development opportunities, acquisition of complementary products or technologies, corporate expansion or relocation of its facilities, working capital and for general corporate purposes.

The Common Shares may not be sold nor may offers to buy the Common Shares be accepted prior to the time the registration statement becomes effective. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the Common Shares in any State in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such State.

StressGen Biotechnologies Corporation is a biopharmaceutical company focused on the development of innovative stress protein-based immunotherapeutics. The Company is developing a broad range of products for the treatment of virally induced infections and related cancers. StressGen has also initiated research studies to evaluate the technology in the treatment of asthma and allergy as well as Hepatitis B. Through its Biochemical Division, StressGen is also an internationally recognized supplier of research products for the study of cellular stress, apoptosis, oxidative stress and neurobiology. These products are used by scientists worldwide.

Copies of the short form prospectus may be obtained on request without charge from BMO Nesbitt Burns Inc., Suite 1700 - 885 West Georgia Street, Vancouver, British Columbia, V6C 3E8 (telephone [phone]).

SOURCE: StressGen Biotechnologies Corp.

[MatzeKlug]

3.10.
StressGen presents early data indicating 75% of patients convert from high grade to low grade dysplasia

Link
http://www.newswire.ca/releases/October2000/03/c9495.html

[MatzeKlug]

3.10.
StressGen presents early data indicating 75% of patients convert from high grade to low grade dysplasia

Link
http://www.newswire.ca/releases/October2000/03/c9495.html

[juniorprimus]

hallo Jungs,

"schön" diese nachricht - nur ich besitze kein brauchbares übersetzungsprogramm.
Was bedeuten diese aussagen, grob unterm strich. Geht´s mit stressgen langfristig bergauf, oder sollte ich den wert liquidieren.
Für eine qualifizierte antwort wäre ich sehr dankbar.

[Spiewi]

Das ist eine gute Nachricht,das sagt,das 75% der Behandelten
Patienten nicht unters Messser muessen.
Spiewi

[Roky18]

Hallo Leute. Ich halte auch seit mehreren Monaten diese Aktie.

Was meint ihr für die Zukunft?

[MatzeKlug]

VICTORIA, BC, Oct 17, 2000 /PRNewswire via COMTEX/ -- StressGen Biotechnologies Corp. (TSE: SSB) announced today that it has successfully closed its public offering of 6,500,000 Common shares at a price of CDN$7.00 per share, representing an additional 500,000 Common shares over the number offered in the preliminary prospectus. Gross proceeds of this offering are CDN$45,500,000, prior to exercise of the over-allotment option.

The underwriting syndicate for the offering was led by BMO Nesbitt Burns Inc., and included CIBC World Markets Inc. and Goepel McDermid Inc.

The net proceeds of this offering will be used primarily to fund the Company`s development program for its lead product candidate HspE7. In addition, a portion of the funds will be used to drive the research and development of new product development opportunities, acquisition of complementary products or technologies, corporate expansion or relocation of its facilities, working capital and for general corporate purposes.

StressGen Biotechnologies Corporation is a biopharmaceutical company focused on the development and commercialization of innovative stress protein- based immunotherapeutics. The Company is developing a broad range of products for the treatment of virally-induced infections and related cancers. StressGen`s lead product HspE7 targets a variety of precancerous and cancerous conditions caused by Human Papillomavirus (HPV). The Company has active Phase II HspE7 studies in women with high-grade cervical dysplasia and cervical cancer, as well as a Phase II study in anal dysplasia. In addition, StressGen plans to initiate a Phase II HspE7 study in genital warts and a Phase III HspE7 study in anal dysplasia before the end of the year. StressGen has also initiated research studies to evaluate the technology in the treatment of asthma and allergy as well as Hepatitis B. Through its Biochemical Division, StressGen is also an internationally recognized supplier of research products for the study of cellular stress, apoptosis, oxidative stress and neurobiology. These products are used by scientists worldwide.

[proteindesigner]

@alle

scheint ja (nach einer langen konsolidierung)wieder musik in die aktie zu kommen.

in kanada aktuell+4%

bis bald,

p.d.

[Andrax]

steigender kurs bei hohem volumen

sieht gut aus

[Andrax]

News from The Globe and Mail




StressGen Biotech (TSE-SSB)
03:30 EDT Tuesday, October 24, 2000


$7.25, up 10 cents

StressGen Biotechnologies Corp., a Victoria-based biopharmaceutical company, will replace Clearnet Communications Inc. in the TSE 300-stock composite index in the wake of Clearnet`s takeover by Telus Corp. In a press release, Standard & Poor`s Canadian Index Operations said StressGen stock will also be added to the S&P/TSE Canadian SmallCap and TSE 200 indexes. The changes were effective after the close of trading yesterday.

[banker.x]

Hallo,

Kann mir jemand sagen, warum der Kurs von STRESSGEN seit Monaten vor sich hintümpelt?

gruss
bk

[MatzeKlug]

STRESSGEN BIOTECHNOLOGIES CORP ("SSB-T") - Added To TSE 300 Composite Index
StressGen Biotechnologies Corp. is pleased to announce that it has been selected to join the Toronto Stock Exchange 300 Composite Index (TSE 300) and has also been added to the Standard & Poor``s/TSE SmallCap Index in the Health Care sector. This inclusion was effective as of the close of business on Monday, October 23rd, 2000.

"I believe this is a milestone for StressGen, and one that reflects both the Company``s emergence as a leader within the biotech industry and also the growing importance of the life sciences sector to our economy," said Daniel Korpolinski, President and CEO of StressGen Biotechnologies. "We are all very proud that StressGen is now a member of this select group of Canadian public companies."

Comprised of 300 of Canada``s larger public companies traded on the Toronto Stock Exchange, the TSE 300 was created in 1977 by the Toronto Stock Exchange and is maintained by S&P. This index is considered a benchmark used to measure the price performance of the broad Canadian equity market. Inclusion in the TSE 300 is made only after review by S&P and in accordance with certain criteria.

StressGen Biotechnologies Corporation is a biopharmaceutical company focused on the development and commercialization of innovative stress protein-based immunotherapeutics. The Company is developing a broad range of products for the treatment of virally-induced infections and related cancers. StressGen``s lead product HspE7 targets a variety of precancerous and cancerous conditions caused by Human Papillomavirus (HPV), a sexually transmitted disease. The Company has active Phase II HspE7 studies in women with high-grade cervical dysplasia and cervical cancer, as well as a Phase II study in anal dysplasia. In addition, StressGen plans to initiate a Phase II HspE7 study in genital warts and a Phase III HspE7 study in anal dysplasia before the end of the year. StressGen has also initiated research studies to evaluate the technology in the treatment of asthma and allergy as well as Hepatitis B. Through its Biochemical Division, StressGen is also an internationally recognized supplier of research products for the study of cellular stress, apoptosis, oxidative stress and neurobiology. These products are used by scientists worldwide.
-
-
-

Top Picks: TD`s Bruce Cooper Picks Small Caps that Won`t Flame Out




Toronto, ONT, October 24 /SHfn -- When he`s shopping for stocks among Canada`s small cap companies, Bruce Cooper finds that it pays to have a stomach for volatility and an appetite for biding his time. Cooper manages the $70-million Canadian Small Cap Fund for TD Asset Management. The fund is up 57% in the past year, and 33% over the past two years. He sails in the often-choppy waters of the $100-million to $1.5-billion market cap range, where a buy-and-hold strategy can pay off. Right now Cooper is cautiously bullish about the outlook for Canada`s small- and mid-caps.

Cooper is a bottom-up investor, seeking out fundamentally sound companies in strong sectors. He looks for significant management ownership stakes, and tries to identify management teams that have track records, even if their new companies don`t. "There probably are hundreds of small cap companies that have interesting ideas and interesting visions," he says. "But there aren`t that many that have actually executed over a reasonably long period of time, so certainly we do try to put an emphasis on the historical track record (of management)."

Cooper looks for significant management ownership stakes, and tries to identify management teams that have track records, even if their new companies don`t.




Investing in small caps means taking on inherent risks. Small caps are vulnerable in rough economic times, and they often don`t have the same management depth of larger competitors. Few of Cooper`s stocks represent more than 2.5% of his portfolio. "What I do to try to mitigate against all that risk is have a relatively large number of positions, so if one or two stocks blow up it`s not going to kill me," he says. Some do blow up, but Cooper has picked four stocks for StockHouse which he thinks are heading in the other direction.

STRESSGEN BIOTECHNOLOGIES CORPORATION [T.SSB]
Cooper is looking for a double from this Vancouver, B.C., biotechnology firm which has just finished Phase II trials of a new drug designed to treat diseases caused by the human papilloma virus - diseases like genital warts, and cervical and anal cancer. The company currently has no sales, but Cooper thinks there`s a high probability its lead drug will come onto the market in 2003 or 2004. He says the stock could start to rise in the short term when the company enters Phase III trials. Cooper thinks the company will get a boost if it announces a partnership with a larger distributor, which he believes is likely. On the other hand, if the drug fails, Cooper knows the stock price will probably crumble.

[Andrax]

Hi an alle gestressten Stressgener, es gibt mal wieder News,
HSPE7 kommt jetzt in ein Phase 3 Versuch, allerdings bringt uns das z.Zt. nur ein Plus von knapp 3% bei ganzen 6550 bis jetzt gehandelten Aktien.


StressGen initiates HspE7 Phase III trial in HPV-related anal dysplasia

07:59 EST Monday, November 06, 2000



CDC reports HPV second only to HIV in US STD related healthcare costs

VICTORIA, BC, Nov. 6 /CNW/ - StressGen Biotechnologies Corp. (TSE: SSB) announced today that it has initiated patient treatment in a Phase III clinical trial to investigate HspE7 as a novel immunotherapeutic for anal dysplasia (AIN) caused by the human papilloma virus (HPV). HPV is one of the most common sexually-transmitted diseases (STDs) in the world. StressGen also has active Phase II HspE7 studies in women with HPV-related cervical dysplasia and cervical cancer, and plans to initiate a Phase II study in genital warts. The Company previously reported preliminary data from the first patients in its open label Phase II trial in anal dysplasia at two scientific conferences, HPV 2000 in Barcelona in July, 2000, and at Cancer Vaccines 2000 in New York City in October, 2000.

"More than 60 patients have now been treated in the Phase II trial, and the positive results observed serve as the basis of the new Phase III trial," said Dr. John Neefe, VP Clinical and Regulatory Affairs of StressGen Biotechnologies. "In addition, observation of responses in patients with various HPV types, including the types most commonly associated with genital warts, reinforce the potential of HspE7 as a broad-based therapeutic for HPV-related diseases."

This is the first trial in StressGen`s Phase III program for the development of HspE7. This double-blind placebo-controlled study will involve 128 patients at multiple centers in the United States. Clinical efficacy will be determined by regression of AIN using standard pathological criteria.

"The initiation of this Phase III trial represents a significant milestone for StressGen. It is a clear indication of the Company`s confidence in the HspE7 clinical program and in our Hsp fusion technology as a platform for developing novel immunotherapeutics," said Daniel Korpolinski, President and CEO of StressGen Biotechnologies. "Public awareness of the link between HPV infection and certain cancers, such as cervical cancer which is screened for in pap tests, has increased significantly. This is important because HPV infection is extremely common and can result in significant morbidity. It is well recognized that existing approaches to treatment do not address the underlying pathology and it is inevitable that demand will grow to look at new approaches to treatment. We believe that HspE7 is well positioned to be seen as a potential solution to this major public health issue."

There are 5.5 million new cases of genital HPV infection diagnosed per year in the US alone, and according to a report published by the Division of STD Prevention, Centers for Disease Control and Prevention, HPV is second only to HIV in STD-related US healthcare costs (http:// www.cdc.gov/nchstp/dstd/Reports--Publications/99HPVReport.htm). Genital HPV infection can cause a variety of precancerous conditions, including anal and cervical dysplasia. Left undiagnosed, or untreated, dysplastic cells can become cancerous. HPV is also responsible for genital warts and laryngeal warts as well as some head and neck cancers.

HspE7 is based on StressGen`s proprietary Hsp fusion technology. HspE7, a recombinant fusion product, is composed of heat shock protein 65 (Hsp65) from Mycobacterium-bovis BCG and the protein E7. As a member of the family of stress proteins, Hsp65 is known to elicit a powerful immune response. The E7 protein is derived from the HPV and is involved in the malignant transformation of epithelial cells. E7 is a tumor-specific antigen and represents a precise target for the immune system attack on abnormal cells.


StressGen Biotechnologies is a biopharmaceutical company focused on the development and commercialization of innovative stress protein-based immunotherapeutics. The Company is developing a broad range of products for the treatment of viral infections and related cancers. StressGen`s lead product HspE7 targets a variety of HPV-related diseases. StressGen has also initiated research studies to evaluate the technology in the treatment of asthma and allergy as well as Hepatitis. Through its Biochemical Division, StressGen is also an internationally recognized supplier of research products for the study of cellular stress, apoptosis, oxidative stress and neurobiology. These products are used by scientists worldwide.


This foregoing press release may contain statements that are not based on historical fact, including, without limitation, statements containing the words "believes", "may", "will", "intends", "plans", "expects" and words of similar import. Such statements may constitute "forward-looking" statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. A number of factors could cause actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements implied by such statements. Such factors include, but are not limited to, those with respect to the timing of regulatory submissions and approvals, the ability of the Company to continue to develop its products (including HspE7), the Company`s ability to maintain or expand its intellectual property position, the timing and success of planned or existing clinical trials and anticipated levels of revenues and expenses and others, all as described Company`s Registration Statement on Form F-10 and other filings with the U.S. Securities and Exchange Commission.

%SEDAR: 00002379E

[MatzeKlug]

Wisst Ihr eigentlich was es heißt ein Produkt in Phase III zu bringen?

I ist schwer 2 ist viel schwerer zu überstehen und wenn die dritte auch noch klappt steht dem neuen Produkt nichts mehr im Weg.

Also Stressgen ist auf dem richtigen Weg.

[MatzeKlug]

CDC reports HPV second only to HIV in US STD related healthcare costs
VICTORIA, BC, Nov. 6 /PRNewswire/ - StressGen Biotechnologies Corp. (TSE: SSB) announced today that it has initiated patient treatment in a Phase III clinical trial to investigate HspE7 as a novel immunotherapeutic for anal dysplasia (AIN) caused by the human papilloma virus (HPV). HPV is one of the most common sexually-transmitted diseases (STDs) in the world. StressGen also has active Phase II HspE7 studies in women with HPV-related cervical dysplasia and cervical cancer, and plans to initiate a Phase II study in genital warts. The Company previously reported preliminary data from the first patients in its open label Phase II trial in anal dysplasia at two scientific conferences, HPV 2000 in Barcelona in July, 2000, and at Cancer Vaccines 2000 in New York City in October, 2000.

"More than 60 patients have now been treated in the Phase II trial, and the positive results observed serve as the basis of the new Phase III trial," said Dr. John Neefe, VP Clinical and Regulatory Affairs of StressGen Biotechnologies. "In addition, observation of responses in patients with various HPV types, including the types most commonly associated with genital warts, reinforce the potential of HspE7 as a broad-based therapeutic for HPV- related diseases."

This is the first trial in StressGen`s Phase III program for the development of HspE7. This double-blind placebo-controlled study will involve 128 patients at multiple centers in the United States. Clinical efficacy will be determined by regression of AIN using standard pathological criteria.

"The initiation of this Phase III trial represents a significant milestone for StressGen. It is a clear indication of the Company`s confidence in the HspE7 clinical program and in our Hsp fusion technology as a platform for developing novel immunotherapeutics," said Daniel Korpolinski, President and CEO of StressGen Biotechnologies. "Public awareness of the link between HPV infection and certain cancers, such as cervical cancer which is screened for in pap tests, has increased significantly. This is important because HPV infection is extremely common and can result in significant morbidity. It is well recognized that existing approaches to treatment do not address the underlying pathology and it is inevitable that demand will grow to look at new approaches to treatment. We believe that HspE7 is well positioned to be seen as a potential solution to this major public health issue."

There are 5.5 million new cases of genital HPV infection diagnosed per year in the US alone, and according to a report published by the Division of STD Prevention, Centers for Disease Control and Prevention, HPV is second only to HIV in STD-related US healthcare costs (http://http://www.cdc.gov/nchstp/dstd/Reports_Publications/99HPVRep… Genital HPV infection can cause a variety of precancerous conditions, including anal and cervical dysplasia. Left undiagnosed, or untreated, dysplastic cells can become cancerous. HPV is also responsible for genital warts and laryngeal warts as well as some head and neck cancers.


Das war schon mal da aber ich habs halt noch mal verdeutlicht.

[Andrax]

News

http://www.globeinvestor.com/servlet/WireFeedRedirect?slug=c…

[Capt.Janeway]

Habe diese News mal überflogen, aber mein English reicht hier nicht mehr aus um die Fachausdrücke ins richtige Licht zu bringen.

Scheint aber positiv zu sein, da der Wert steigt !

[MatzeKlug]

Stressgen reports third quarter financial results

06:00 EST Wednesday, November 15, 2000



Underwriters exercise their over-allotment option


THE FOLLOWING RELEASE WAS ORIGINALLY TRANSMITTED ON TUESDAY,

NOVEMBER 14, 2000.

VICTORIA, BC, Nov. 14 /CNW/ - Stressgen Biotechnologies Corp. (TSE: SSB) today released its financial results for the quarter ending September 30, 2000. All amounts, unless otherwise specified, are in Canadian dollars. For the three months ended September 30, 2000, Stressgen reported net losses of $4.17 million or $0.10 cents per common share compared with a net loss of $2.86 million or $0.10 cents per common share in the same period in 1999. For the nine months ended September 30, 2000, the company reported net losses of $14.33 million or $0.38 cents per common share compared with a net loss of $10.51 million or $0.35 cents per common share in the same period in 1999. The increased losses reflect the advancement of multiple Phase II clinical trials of the company`s lead product, HspE7, and the development of the company`s organizational structure to support this and other research and development programs.

The Company reported revenues of approximately $4.40 million for the first nine months of 2000, compared to $3.17 million reported in 1999. This increase is attributable to 24% increase in biochemical product sales from $2.47 million for the first nine months of 1999 to $3.08 million for the first nine months of 2000. Also contributing to the growth in revenues is an 88% increase in interest and other income from $0.70 million for the first nine months of 1999 to $1.32 million for the same period of 2000. Cash and short- term investments equaled $31.89 million on September 30, 2000.

"We continued to make significant progress in the third quarter in the advancement of the HspE7 clinical program and gained recognition as leader in both the heat shock protein and immunotherapeutics arenas," said Daniel Korpolinski, President and CEO of Stressgen. "The Company has met its milestones for this quarter and remains on track for the next. With the completion of the recent financing we are well positioned to move ahead aggressively in both our clinical programs and research and development."


RECENT ACCOMPLISHMENTS

The week of July 26, 2000, Stressgen reported important preliminary data from the first patients in its open label Phase II trial in anal dysplasia (AIN) at the 18th International Papillomavirus Conference, a scientific symposium, held in Barcelona, Spain. This data established activity of HspE7, a novel immunotherapeutic, in the treatment of HPV-related anal dysplasia. The Company also reported new data on HspE7`s mechanism of action, as well as data from a healthy volunteer trial. Following the third quarter, Stressgen also presented updated Phase II AIN data at the Cancer Vaccines 2000 conference held in New York as well as the 2nd International Heat Shock Proteins conference in Connecticut. These Phase II data also demonstrated activity of HspE7, in the treatment of HPV-related anal dysplasia (AIN). Further, observation of responses in patients with various HPV types including the types most commonly associated with genital warts reinforce the potential of HspE7 as a broad-based therapeutic for HPV-related diseases.

In its HspE7 clinical program, Stressgen continued to make rapid advances. The Company closed enrollment in its Phase II AIN trial at 85 patients and continues to enroll in its open label trial. The results observed to date in the Phase II AIN trials served as the basis for the new Phase III trial in AIN which was announced on November 6. In addition, the Company closed enrollment in the Phase II high-grade cervical dysplasia (CIN II/III) and initiated a Phase II cervical cancer trial. Stressgen plans to initiate a Phase II trial for genital warts and continues to evaluate additional indications for HspE7.

The Company also made significant strides in this quarter with further scientific affirmation of its proprietary stress protein fusion technology. Stressgen scientists and collaborators published an article in the scientific journal Clinical Experimental Immunology (121:216-225) confirming that HspE7 invokes a potent cellular immune response and supporting the potential application of this novel therapeutic approach in the treatment of immunocompromised patients. These preclinical studies indicated that the recombinant fusion protein is required for tumor regression and long-term survival. More importantly, the studies clearly established that components of the fusion protein, alone or in a mixture, are not effective. These data reinforce the potential of Hsp fusions as a platform technology for the development of novel immunotherapeutics.

As previously announced, on October 17th, Stressgen successfully closed the offering of 6,500,000 Common shares at a price of CDN$7.00 per share, for total gross proceeds of CDN$45.50 million. Stressgen now announces that the underwriters for the offering have exercised a portion of their over-allotment option to acquire an additional 404,100 common shares at CDN$7.00 per share for additional gross proceeds of CDN $2.83 million. The issuance of these shares is expected to close shortly. The net proceeds of the offering will be used primarily to fund the Company`s development program for its lead product candidate HspE7. In addition, a portion of the funds will be used to drive the research and development of new product development opportunities, acquisition of complementary products or technologies, corporate expansion or relocation of its facilities, working capital and for general corporate purposes.

Another indication of the positive advancements Stressgen has made over the quarter, was the addition of the Company to the TSE 300 composite index and to the Standard & Poor`s/TSE SmallCap Index in the Health Care sector as of the close of business on Monday, October 23, 2000. This milestone also reflects the increasing recognition Stressgen has gained as a leading biotechnology company.


Stressgen Biotechnologies Corporation is focused on the development and commercialization of novel stress protein-based immunotherapeutics. The Company is currently conducting clinical trials for HspE7 in the treatment of sexually transmitted diseases caused by the Human Papillomavirus (HPV). The Company has an active Phase III trial for HPV-related anal dysplasia and two Phase II trials in cervical cancer and cervical dysplasia underway. Stressgen also plans to initiate a Phase II trial in genital warts. The Company is developing a broad range of stress protein-based therapeutic products for other diseases including Hepatitis and HIV and has also initiated studies to evaluate the heat shock proteins in asthma and allergy. Stressgen is an internationally recognized supplier of research products for the study of cellular stress, apoptosis, oxidative stress and neurobiology. These products are used by scientists worldwide.

Stressgen has scheduled a public conference call for Tuesday, November 14, 2000 at 2 pm (Pacific Time) to discuss the quarterly results and update. To participate, call 888-313-1094 in Canada, the United States or internationally. This call will be recorded for playback by calling 800-558- 5253 and entering reservation number 16828978 and is available November 14 through November 21, 2000.


This foregoing press release may contain statements that are not based on historical fact, including, without limitation, statements containing the words "believes", "may", "will", "intends", "plans", "expects" and words of similar import. Such statements may constitute "forward-looking" statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. A number of factors could cause actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements implied by such statements. Such factors include, but are not limited to, those with respect to the timing of regulatory submissions and approvals, the ability of the Company to continue to develop its products (including HspE7), the Company`s ability to maintain or expand its intellectual property position, the timing and success of planned or existing clinical trials and anticipated levels of revenues and expenses and others, all as described Company`s Registration Statement on Form F-10 and other filings with the U.S. Securities and Exchange Commission.

[Andrax]

gestern wurden über 600.000 Aktien gehandelt, ca das 10-fache des Durchschnittsvolumens, kann sich jemand einen grund dafür denken? News gibt es mE nicht. Komisch...

http://investdb.theglobeandmail.com/invest/investSQL/gx.pric…

[banker.x]

Hallo,

Kann mir jemand sagen warum die Aktie seit Monaten so vor sich hintümpelt. Scheinbar haben die Fondsgesellschaften kein sehr großes Interesse an diesem Papier? Oder ist vielleicht die Produktpipeline zu schwach?

[puhvogel]

http://biz.yahoo.com/prnews/001114/ny_antigen.html

Antigenics Wins Crucial Patent Battle With StressGen

NEW YORK, Nov. 14 /PRNewswire/ -- The European Patent Office (EPO) revoked in its entirety a patent issued to StressGen Biotechnologies Corp. relating to
the use of heat shock proteins (HSPs) for the treatment of cancer and infectious diseases. Antigenics (Nasdaq: AGEN - news) filed an opposition to the StressGen
patent in June 1996 on grounds that the patent was invalid. After Antigenics filed its opposition, StressGen amended the claims to exclude patient-specific treatment
of cancer. The EPO issued a preliminary ruling in June 1998 that the patent should be revoked. In response, StressGen further amended the patent. The amended
patent was finally revoked at today`s hearing in Munich, Germany.
``After today`s ruling, Antigenics remains the only company to hold patents in the promising field of therapies for cancer and infectious diseases based on the rapidly
emerging HSP technology,`` said Garo H. Armen, Ph.D., chairman and CEO of Antigenics. ``We are pleased with the EPO`s decision which allows us to maintain
our worldwide leadership position in this field.``
Antigenics has been issued 15 U.S. patents and has corresponding European filings covering use of HSPs for the treatment of all types of cancers, infectious
diseases and degenerative diseases. The company`s technology is rapidly growing and is well recognized in the field of immunology (see http://www.antigenics.com
or http://www.hspimmunity.com).

[TheFrog]

Schaut doch mal rein: www.brokerstalk.de.vu

[gol]

mal wieder was von neues

Stressgen initiates Phase II genital warts trial
16:01 EST Tuesday, January 09, 2001


Trial Expands Broad-Spectrum Activity of HspE7 in HPV-Related Diseases

VICTORIA, BC, Jan. 9 /CNW/ - Stressgen Biotechnologies Corp. (TSE: SSB) announced today that it has initiated a Phase II clinical trial to investigate HspE7 as a novel immunotherapeutic for genital warts caused by the human papillomavirus (HPV). This double-blind placebo-controlled study will involve 52 patients at multiple study centers in the United States. Effectiveness will be assessed as regression of warts by standardized clinical criteria. Stressgen also has an active Phase III HspE7 study for HPV-related anal dysplasia and two Phase II studies in women with HPV-related cervical dysplasia and cervical cancer.

HPV is one of the most common sexually transmitted diseases (STDs) in the world. There are 5.5 million new cases of genital HPV infection diagnosed per year in the US alone, of which over 1 million represent cases of genital warts. In addition to warts, genital HPV infection can cause a variety of precancerous conditions, including anal and cervical dysplasia. Left undiagnosed, or untreated, dysplastic cells can become cancerous. HPV is also responsible for laryngeal warts as well as some head and neck cancers.

"The initiation of this trial represents the achievement of another milestone for Stressgen," said Daniel Korpolinski, President and CEO of Stressgen Biotechnologies. "Genital warts in conjunction with high-grade cervical and anal dysplasia represent over 2.2 million cases of the genital HPV infections each year in the US. It is clear that these diseases are a major public health issue and better treatments need to be developed. We believe that HspE7 may offer a novel therapeutic solution."


Stressgen Biotechnologies is a biopharmaceutical company focused on the development and commercialization of innovative stress protein-based immunotherapeutics. The Company is developing a broad range of products for the treatment of viral infections and related cancers. Stressgen`s lead product HspE7 targets a variety of HPV-related diseases. Stressgen has also initiated research studies to evaluate the technology in the treatment of asthma and allergy as well as Hepatitis. Stressgen is also an internationally recognized supplier of research products for the study of cellular stress, apoptosis, oxidative stress and neurobiology. These products are used by scientists worldwide.


This foregoing press release may contain statements that are not based on historical fact, including, without limitation, statements containing the words "believes", "may", "will", "intends", "plans", "expects" and words of similar import. Such statements may constitute "forward-looking" statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. A number of factors could cause actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements implied by such statements. Such factors include, but are not limited to, those with respect to the timing of regulatory submissions and approvals, the ability of the Company to continue to develop its products (including HspE7), the Company`s ability to maintain or expand its intellectual property position, the timing and success of planned or existing clinical trials and anticipated levels of revenues and expenses and others, all as described Company`s Registration Statement on Form F-10 and other filings with the U.S. Securities and Exchange Commission.

%SEDAR: 00002379E

[Klaudius]

Hallo Leute,

hat jemand Informationen über Stressgen und warum kann die Aktie nicht richtig erholen.

Danke.

[study]

läuft doch ganz gut die letzten Tage gegen den Trend..